A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis

James J. O'Meara, Robert A. McNutt, Arthur T. Evans, Stacy W. Moore, Stephen Downs

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background. It is uncertain whether patients with proximal deep-vein thrombosis should be treated with streptokinase followed by intravenous heparin or with intravenous heparin alone. Published reports indicate that streptokinase plus heparin increases the risk of bleeding, including central nervous system bleeding and death, but decreases the risk of postphlebitic syndrome. Previous recommendations regarding these treatments have not considered patients' preferences or the values they attach to the possible outcomes of therapy. Methods. We used decision analysis to combine published estimates of the probabilities of various adverse outcomes of treatment (bleeding, pulmonary embolism, postphlebitic syndrome, and death) with the values patients placed on these outcomes. We questioned 36 patients about the values they attached to each outcome. Sixteen patients had had deep-vein thrombosis, and 20 had not. Results. By the values they attached to the outcomes, all 36 patients indicated that they were unwilling to accept an increased risk of death to avoid postphlebitic syndrome. According to the decision analysis, heparin alone was the better treatment for all 36 patients. As compared with streptokinase plus heparin, heparin alone provided 29 days of additional life expectancy over the predicted life expectancy of 20 years. Although the difference between the two treatments was small, heparin alone remained the better treatment in sensitivity analyses that examined the reasonable ranges of probabilities of the clinical outcomes. Conclusions. The values patients placed on the outcomes of treatment for deep-vein thrombosis support the use of heparin alone over the combined use of streptokinase and heparin.

Original languageEnglish (US)
Pages (from-to)1864-1869
Number of pages6
JournalNew England Journal of Medicine
Volume330
Issue number26
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Streptokinase
Decision Support Techniques
Venous Thrombosis
Heparin
Postphlebitic Syndrome
Hemorrhage
Life Expectancy
Therapeutics
Patient Preference
Pulmonary Embolism
Central Nervous System

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. / O'Meara, James J.; McNutt, Robert A.; Evans, Arthur T.; Moore, Stacy W.; Downs, Stephen.

In: New England Journal of Medicine, Vol. 330, No. 26, 1994, p. 1864-1869.

Research output: Contribution to journalArticle

O'Meara, James J. ; McNutt, Robert A. ; Evans, Arthur T. ; Moore, Stacy W. ; Downs, Stephen. / A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. In: New England Journal of Medicine. 1994 ; Vol. 330, No. 26. pp. 1864-1869.
@article{df6661abceae4010977f7751d1dfc860,
title = "A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis",
abstract = "Background. It is uncertain whether patients with proximal deep-vein thrombosis should be treated with streptokinase followed by intravenous heparin or with intravenous heparin alone. Published reports indicate that streptokinase plus heparin increases the risk of bleeding, including central nervous system bleeding and death, but decreases the risk of postphlebitic syndrome. Previous recommendations regarding these treatments have not considered patients' preferences or the values they attach to the possible outcomes of therapy. Methods. We used decision analysis to combine published estimates of the probabilities of various adverse outcomes of treatment (bleeding, pulmonary embolism, postphlebitic syndrome, and death) with the values patients placed on these outcomes. We questioned 36 patients about the values they attached to each outcome. Sixteen patients had had deep-vein thrombosis, and 20 had not. Results. By the values they attached to the outcomes, all 36 patients indicated that they were unwilling to accept an increased risk of death to avoid postphlebitic syndrome. According to the decision analysis, heparin alone was the better treatment for all 36 patients. As compared with streptokinase plus heparin, heparin alone provided 29 days of additional life expectancy over the predicted life expectancy of 20 years. Although the difference between the two treatments was small, heparin alone remained the better treatment in sensitivity analyses that examined the reasonable ranges of probabilities of the clinical outcomes. Conclusions. The values patients placed on the outcomes of treatment for deep-vein thrombosis support the use of heparin alone over the combined use of streptokinase and heparin.",
author = "O'Meara, {James J.} and McNutt, {Robert A.} and Evans, {Arthur T.} and Moore, {Stacy W.} and Stephen Downs",
year = "1994",
doi = "10.1056/NEJM199406303302605",
language = "English (US)",
volume = "330",
pages = "1864--1869",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "26",

}

TY - JOUR

T1 - A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis

AU - O'Meara, James J.

AU - McNutt, Robert A.

AU - Evans, Arthur T.

AU - Moore, Stacy W.

AU - Downs, Stephen

PY - 1994

Y1 - 1994

N2 - Background. It is uncertain whether patients with proximal deep-vein thrombosis should be treated with streptokinase followed by intravenous heparin or with intravenous heparin alone. Published reports indicate that streptokinase plus heparin increases the risk of bleeding, including central nervous system bleeding and death, but decreases the risk of postphlebitic syndrome. Previous recommendations regarding these treatments have not considered patients' preferences or the values they attach to the possible outcomes of therapy. Methods. We used decision analysis to combine published estimates of the probabilities of various adverse outcomes of treatment (bleeding, pulmonary embolism, postphlebitic syndrome, and death) with the values patients placed on these outcomes. We questioned 36 patients about the values they attached to each outcome. Sixteen patients had had deep-vein thrombosis, and 20 had not. Results. By the values they attached to the outcomes, all 36 patients indicated that they were unwilling to accept an increased risk of death to avoid postphlebitic syndrome. According to the decision analysis, heparin alone was the better treatment for all 36 patients. As compared with streptokinase plus heparin, heparin alone provided 29 days of additional life expectancy over the predicted life expectancy of 20 years. Although the difference between the two treatments was small, heparin alone remained the better treatment in sensitivity analyses that examined the reasonable ranges of probabilities of the clinical outcomes. Conclusions. The values patients placed on the outcomes of treatment for deep-vein thrombosis support the use of heparin alone over the combined use of streptokinase and heparin.

AB - Background. It is uncertain whether patients with proximal deep-vein thrombosis should be treated with streptokinase followed by intravenous heparin or with intravenous heparin alone. Published reports indicate that streptokinase plus heparin increases the risk of bleeding, including central nervous system bleeding and death, but decreases the risk of postphlebitic syndrome. Previous recommendations regarding these treatments have not considered patients' preferences or the values they attach to the possible outcomes of therapy. Methods. We used decision analysis to combine published estimates of the probabilities of various adverse outcomes of treatment (bleeding, pulmonary embolism, postphlebitic syndrome, and death) with the values patients placed on these outcomes. We questioned 36 patients about the values they attached to each outcome. Sixteen patients had had deep-vein thrombosis, and 20 had not. Results. By the values they attached to the outcomes, all 36 patients indicated that they were unwilling to accept an increased risk of death to avoid postphlebitic syndrome. According to the decision analysis, heparin alone was the better treatment for all 36 patients. As compared with streptokinase plus heparin, heparin alone provided 29 days of additional life expectancy over the predicted life expectancy of 20 years. Although the difference between the two treatments was small, heparin alone remained the better treatment in sensitivity analyses that examined the reasonable ranges of probabilities of the clinical outcomes. Conclusions. The values patients placed on the outcomes of treatment for deep-vein thrombosis support the use of heparin alone over the combined use of streptokinase and heparin.

UR - http://www.scopus.com/inward/record.url?scp=0028365495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028365495&partnerID=8YFLogxK

U2 - 10.1056/NEJM199406303302605

DO - 10.1056/NEJM199406303302605

M3 - Article

VL - 330

SP - 1864

EP - 1869

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 26

ER -